To stimulate the CD16-mediated activation of NK cells, we incubated them with the target Burkitt lymphoma cell line Raji, pre-coated with the anti-CD20 therapeutic monoclonal antibody RTX. This evidence concerns the gene FCGR3A and Burkitt lymphoma.